---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-25-008182"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:46:42.917865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic

## Summary
- Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
- Net cash used in ops $3.6M (-33% YoY); post-quarter raised $6.1M net from public offering.
- Signed Research License and Option Agreement for APS with Werfen; Co-Marketing Agreement with Hologic.
- In discussions with ~10 leading diagnostic/liquid biopsy companies for further licensing deals.
- Anticipates peer-reviewed publications on Nu.Q platform and Capture-Seq technology.

## SEC filing metadata
- accession: 0001477932-25-008182
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793225008182/0001477932-25-008182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793225008182/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-25-008182
- JSON: https://secwatch.observer/filing/0001477932-25-008182.json
- Plain text: https://secwatch.observer/filing/0001477932-25-008182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.